I’m a radiation oncologist. I treat cancer for a living. And for years, I kept running into the same problem: I’d see patients with cancers that obesity clearly contributed to — endometrial, esophageal, colorectal — and I had nothing useful to offer them about their weight. I could explain the biology. I could cite the data. But I couldn’t actually help them lose weight.

That incompetence bothered me enough that I did something about it. I got board-certified in obesity medicine through the American Board of Obesity Medicine, and since 2023 I’ve been managing medical weight loss in my clinic — GLP-1 receptor agonists, phentermine, topiramate, combination therapy, real follow-up. I now treat cancer and its most common modifiable cause in the same practice.

This piece lays out the evidence connecting obesity to cancer, explains the biology, and then shows what happens when you actually intervene — including the parts nobody talks about: insurance denials, forced medication switches, weight regain during drug holidays, and the uterine cancer patient I couldn’t help.

The 13 Cancers

Obesity is the second leading modifiable cause of cancer in the United States, behind tobacco. The CDC and NCI describe overweight and obesity as linked to higher risk of 13 cancers. IARC and the European Code Against Cancer go further and frame the relationship in causal terms. Either way, the list is the same:

• Esophageal adenocarcinoma
• Postmenopausal breast
• Colorectal
• Endometrial (uterine)
• Gallbladder
• Gastric cardia
• Kidney (RCC)
• Liver (HCC)
• Ovarian
• Pancreatic
• Thyroid
• Meningioma
• Multiple myeloma

These aren’t marginal risk increases. For the two highest-impact sites — endometrial cancer and esophageal adenocarcinoma — NCI data show roughly 7-fold and 5-fold increases in risk with severe obesity. The 2019 U.S. attributable-fraction estimates are striking:

Obesity is the dominant modifiable risk factor for several common malignancies. The breast cancer association is specifically postmenopausal — a distinction that matters for patient counseling.

Most patients don’t know any of this. CDC Vital Signs data from 2017 showed that more than half of Americans were unaware that overweight and obesity increase cancer risk. AICR’s more recent survey puts awareness around 62% — better, but still leaving roughly four in ten adults in the dark about one of the leading preventable causes of cancer. In my clinic, most of the patients I see for weight management have never been told by a physician that their weight is a cancer risk factor.

Does Losing Weight Actually Prevent Cancer?

Establishing causation is one thing. Proving that weight loss reverses the risk is harder, and the honest answer is more qualified than most summaries let on.

Endometrial and postmenopausal breast cancer have the strongest direct human evidence. In the Women’s Health Initiative observational cohort, postmenopausal women who lost at least 5% of body weight had lower endometrial cancer risk (HR 0.71). Among women with obesity who intentionally lost weight, the reduction was sharper — HR 0.44, a 56% reduction.

For postmenopausal breast cancer, a 2020 pooled prospective analysis of women over 50 found a dose-response relationship. Compared to women with stable weight, those with sustained weight loss had HR 0.87 for loss greater than 2 up to 4.5 kg, HR 0.84 for 4.5 to under 9 kg, and HR 0.74 for 9 kg or more. The associations were considerably stronger — HR 0.82, 0.75, and 0.68 across the same categories — in women who were not on menopausal hormone therapy at the start of follow-up. Both the overall finding and the stronger signal in non-hormone-users support the idea that intentional weight loss reduces postmenopausal breast cancer risk.

Colorectal and prostate cancer have probable but weaker evidence. NCI’s fact sheet notes some studies showing lower risk after weight loss, but the direct data isn’t as strong. Large bariatric surgery cohorts broaden the signal: a major U.S. cohort showed lower overall and obesity-related cancer incidence after surgery, with especially consistent reductions in postmenopausal breast, endometrial, colon, and pancreatic cancer. But site-specific findings aren’t uniform — a Swedish cohort actually reported higher kidney cancer incidence after bariatric surgery — and none of this comes from randomized trials. Surgical populations also differ from medical weight loss patients in ways that matter.

For the remaining obesity-associated cancers — gallbladder, thyroid, ovary, meningioma, multiple myeloma — direct intentional-weight-loss prevention data are thin, even though obesity clearly raises their risk.

Why Fat Causes Cancer

Five interlocking mechanisms, not one.

Chronic hyperinsulinemia from insulin resistance drives the PI3K/AKT/mTOR pathway, promoting cell proliferation and suppressing apoptosis while increasing IGF-1 bioavailability by suppressing its binding proteins. IGF-1 itself activates both PI3K/AKT and MAPK/ERK cascades, driving cell division and epithelial-to-mesenchymal transition — well-characterized in breast, endometrial, and colorectal cancers. Adipose tissue hypertrophy recruits M1 macrophages that release TNF-alpha, IL-6, and IL-1beta, activating NF-kB and STAT3 — transcription factors that drive pro-survival and angiogenic gene programs, particularly implicated in GI, liver, and esophageal cancers. In postmenopausal women, peripheral aromatase in fat tissue converts androgens to estrogen, making adipose tissue the dominant estrogen source and driving proliferation of ER-positive breast and endometrial cells. And adipokine dysregulation — elevated leptin acting as a mitogen, reduced adiponectin removing a key AMPK-mediated brake on mTOR and NF-kB — compounds all of the above.

These pathways reinforce each other. An obese patient doesn’t have one oncogenic mechanism. They have five, running simultaneously.

Obesity Will Surpass Smoking

The Global Burden of Disease Study (2019, Lancet) ranked the top three cancer risk factors globally: smoking, alcohol, and high BMI. But smoking rates keep falling while obesity prevalence keeps rising. Cancer Research UK projected in 2018 that obesity will surpass smoking as the leading preventable cause of cancer in women by approximately 2043. Among nonsmokers in the U.S., adiposity accounts for 15–16% of all incident carcinomas — the dominant modifiable risk factor in the growing majority of Americans who have never smoked.

The comparison matters because of what it reveals about infrastructure. Smoking cessation has warning labels, taxation, quitlines, insurance-mandated pharmacotherapy, FDA regulation, public awareness campaigns, and physician training. Obesity has almost none of this. Weight management drugs face systematic coverage barriers. Medicare’s medical nutrition therapy benefit is largely limited to diabetes, kidney disease, and recent kidney transplant — expanding it to cancer patients has required separate legislative effort. Dietitian services are largely uninsured in outpatient oncology. We built a national apparatus to help people stop smoking. We have not built one to help people lose weight.

Oncologists Don’t Address It

An AICR/ASCO workforce survey of 971 U.S. oncology providers found that during active treatment, 72% assessed BMI, but only 24% routinely referred patients to weight management interventions. The referral rate after treatment was 33%. Nearly half — 46% — rarely or never referred overweight or obese patients during active therapy. In EHR data, only 39% of breast cancer patients with obesity had any documented weight-related communication with their oncology clinician. In uterine cancer survivors — the cancer most attributable to obesity — only 50% received any weight or lifestyle counseling, and only 6% were referred to a nutritionist.

In my own experience, nobody has ever pushed back on weight counseling. The problem is simpler: nobody talks about it. It’s not that oncologists disagree with the evidence. It’s that weight never makes it onto the problem list, never gets discussed at tumor board, never gets a referral. We diagnose cancers that obesity caused, treat them with therapies that cause more weight gain, and never address the underlying modifiable risk factor.

After Diagnosis, Obesity Still Matters

Excess adiposity is associated with worse outcomes after diagnosis in breast, prostate, colorectal, and multiple myeloma — higher recurrence and progression, higher lymphedema rates after breast treatment, worse urinary incontinence after radical prostatectomy, and higher local recurrence in rectal cancer.

But whether intentional weight loss after a cancer diagnosis actually reduces recurrence or improves survival is a different question, and the honest answer is that we don’t know yet. There is not a single cancer where this is definitively proven. Breast cancer is the best-studied setting — randomized trials show real weight loss and favorable biomarker changes in survivors, and the BWEL trial reported successful 1-year weight loss outcomes — but the endpoint that matters, recurrence and survival, remains unresolved. ASCO’s guideline for active treatment states that evidence for intentional weight-loss interventions is “very limited.”

This doesn’t mean weight loss after diagnosis is pointless. The comorbidity benefits — improved blood pressure, glucose control, functional capacity, treatment tolerability — are real. And the biological plausibility is strong: if the five oncogenic mechanisms I described are actively promoting tumor growth, reducing them should help. But I won’t claim the survival data is there when it isn’t. The evidence-based framing is: weight management improves treatment tolerability, comorbidity burden, and quality of life — and may reduce cancer recurrence, though this hasn’t been definitively demonstrated.

Cancer Treatment Causes Weight Gain

Adjuvant breast cancer chemotherapy is the best-documented setting — over a third of women gain more than 5% of body weight during treatment, with shifts toward more fat mass and less lean mass, especially in premenopausal women and those experiencing treatment-induced menopause. Androgen deprivation therapy for prostate cancer produces remarkably consistent changes: within 12 months, men typically gain 1.8% body weight, increase fat mass by 11%, and lose nearly 4% lean mass. Corticosteroids — used for antiemesis, cerebral edema, and in hematologic regimens — increase appetite, promote central fat deposition, and cause fluid retention.

Aromatase inhibitors are a more nuanced story than they’re often made out to be. Trials like ATAC and IBIS-II did not show clear excess weight gain on anastrozole versus tamoxifen or placebo, so “AIs cause weight gain” is overstated. What’s better supported is that aromatase inhibitors may drive unfavorable changes in fat-to-lean mass ratio and, in more recent work, may blunt the response to anti-obesity medications in breast cancer survivors. That’s narrower but more defensible — and it’s the framing I use when counseling AI patients who are trying to lose weight. Late endocrine injury from cranial radiation or hypothalamic surgery in childhood cancer survivors also creates lifelong obesity risk requiring proactive surveillance.

The cycle is vicious: obesity contributes to a cancer diagnosis, and several of the treatments we use for that cancer make the obesity harder to treat.

GLP-1 Receptor Agonists May Independently Reduce Cancer Risk

There’s an emerging signal that GLP-1 RAs reduce cancer risk beyond what weight loss alone would predict. A 2024 retrospective cohort of approximately 1.1 million patients in the TriNetX database found lower rates of several obesity-associated cancers in GLP-1 RA users compared with matched controls. A 2025 matched cohort analysis in JAMA Oncology of 43,317 GLP-1 RA users found lower overall cancer incidence (13.6 versus 16.4 per 1,000 person-years), with statistically significant site-specific reductions in endometrial, ovarian, and meningioma cancers — not the colorectal, liver, and pancreatic pattern that sometimes gets cited secondhand.

Mechanistically, a semaglutide study published in the Journal of Experimental & Clinical Cancer Research showed that GLP-1 receptor activation on pancreatic cancer-associated fibroblasts reduced collagen proline hydroxylation and increased T-lymphocyte infiltration — a direct anti-tumor stromal effect that a subsequent JCI review discussed in more detail. This suggests the signal may not be solely weight-mediated.

RCT-level data is more cautious. Silverii et al.’s 2025 meta-analysis of 50 randomized trials (over 102,000 participants) found no overall cancer risk difference, a possible reduction in uterine cancer in obesity trials, and a possible thyroid cancer signal. The thyroid finding needs context: some real-world evidence published later in 2025 suggested no overall long-term increase in thyroid cancer risk and argued that the early signal may reflect detection bias from increased screening in patients on GLP-1 therapy. The safest framing is that a thyroid signal has appeared in some analyses but is not established.

We don’t have definitive RCT proof that GLP-1 RAs prevent cancer. The observational signal is consistent, biologically plausible, and large. If even half the effect is real, these drugs represent one of the most consequential secondary benefits of any medication class in decades.

What We’re Actually Doing About It

I’ve been managing medical weight loss in my radiation oncology clinic since 2023. About 25 patients on active management, using semaglutide, tirzepatide, phentermine, topiramate, and combination therapy. Across patients with documented follow-up, my panel has lost approximately 855 pounds total, averaging about 47.5 pounds per patient and roughly 20% total body weight loss. The greatest individual result is over 125 pounds lost — more than 40% of starting body weight.

Here’s what makes those numbers particularly meaningful: the clinical thresholds for comorbidity improvement are remarkably low. Current obesity guidelines, including the VA/DoD clinical practice guideline and the AHA/ACC/TOS guideline for management of overweight and obesity in adults, converge on a familiar hierarchy. About 5% total body weight loss typically improves glycemia, blood pressure, triglycerides, and HDL. Around 10% is often enough for obstructive sleep apnea, fatty liver disease, and meaningful functional improvement. And beyond 15%, you start seeing major metabolic benefit and sometimes diabetes remission. My patients are averaging 20% — four times the threshold at which blood pressure and blood sugar start to improve.

The downstream effects are concrete. Patients crossing back from prediabetes to normal A1C levels. Blood pressures normalizing without medication changes. Triglycerides dropping from elevated to normal. Liver enzymes normalizing in patients with fatty liver disease. These are conditions that independently drive cancer risk, and they’re resolving with weight loss alone.

The human stories are what stay with you. One patient started at 450 pounds and couldn’t walk from a parking lot to a courthouse. Now he walks at normal pace in crowds, goes to the gym, lifts dumbbells, and estimates a 99% reduction in his joint pain. His wedding ring fell off because his hands got so much smaller. A breast cancer survivor who lost over 60 pounds set herself a goal: climb out of the water onto a dock at an alumni rowing event, unassisted. She did it. A 27-year-old woman reports dramatically improved energy and exercise tolerance after losing over 60 pounds — she can climb stairs without stopping. A patient with hereditary spastic paraplegia, a progressive neurological condition that severely limits mobility, lost 40 pounds and noticeably improved her functional capacity despite a disease that’s supposed to only get worse. Multiple patients describe the effect of GLP-1 therapy on food obsession as transformative — one called it “methadone for heroin addicts.” The constant preoccupation with food simply stopped.

The Real-World Mess

Clinical trial data is clean. Real-world obesity treatment is not. Every week I spend hours on insurance — we do a few GLP-1 prior authorizations per week, and each one takes 20 to 25 minutes. That’s clinical time that could go to patients, spent arguing with payers instead.

Prior authorization is constant and arbitrary. One patient’s insurer requires a new PA every month, for each dose change. Another had a PA approved through August, then received coverage termination notice in December. A third had her prescription rejected because the payer flagged that she’d “exceeded the maximum quantity of starter doses for the calendar year” — she’d restarted after a treatment gap and was being penalized for having previously titrated up.

Formulary restrictions force patients onto medications that harm them. Two patients were doing well on tirzepatide (Zepbound) — losing weight, tolerating it well, no side effects — when their insurers forced them onto semaglutide (Wegovy) as the “preferred formulary alternative.” Both developed severe gastroesophageal reflux: nocturnal acid reflux, constant eructation, nausea, vomiting, and lost all appetite suppression. One said she didn’t want to “live like this.” Both are now in formal appeal with medical necessity letters documenting the differential tolerability. One needed an endoscopy to evaluate for erosive changes caused by the forced switch.

Insurance changes disrupt treatment entirely. When one patient’s husband lost his job, her plan changed and the new one didn’t cover Zepbound for obesity. Forced medication switch, restart from the lowest dose, months of lost progress. Some insurers cover nothing at all — one patient with a BMI of 47.2 and multiple comorbidities including hypertension, hyperlipidemia, prediabetes, and obstructive sleep apnea has insurance that covers zero anti-obesity medications. Not Wegovy, not Zepbound, not Saxenda. She’s on phentermine and topiramate because they’re the only affordable option. She’s lost 48 pounds. She’d likely lose more on a GLP-1 RA but can’t access one.

Drug holidays are the most painful pattern. Patients interrupt treatment — sometimes by choice, sometimes forced by insurance or life events — and the weight returns every time. One patient took a voluntary two-week break and immediately experienced rebound appetite and gained five pounds. A longer one-month break cost her ten pounds and months of progress. A 27-year-old became pregnant and stopped; after delivery and an 8-month gap, she’s restarting 43 pounds above her lowest weight. A breast cancer survivor held medication for surgery, regained weight, and had to re-titrate from scratch. Each restart requires full re-titration from the lowest dose — weeks to months of subtherapeutic dosing before reaching the dose that was previously working.

The patients who fell through — about five of my panel with no documented follow-up — all had the same story: inadequate insurance coverage. They couldn’t sustain access to medication, and they stopped coming.

What This Adds Up To

Obesity is linked to at least 13 cancer types through five convergent biological mechanisms, and the international cancer agencies increasingly frame the relationship as causal. Losing weight prevents at least two cancers — endometrial and postmenopausal breast — with strong direct evidence, and likely prevents more based on bariatric cohort data. After diagnosis, obesity worsens outcomes, but we can’t yet prove that intentional weight loss reduces recurrence for any cancer. Cancer treatment itself causes weight gain, creating a cycle. Medical weight management works. GLP-1 RAs may independently reduce cancer risk — an emerging signal that, if confirmed, would rival smoking cessation as a cancer prevention tool. And the system makes treatment as difficult as possible.

Every oncologist should screen for obesity at diagnosis and connect patients to weight management with the same rigor applied to smoking cessation. Fewer than a quarter do during active treatment. Every insurer should cover anti-obesity medications with the formulary flexibility given to antihypertensives. Forcing a patient off a working medication onto one that causes treatment-limiting side effects because of a formulary preference is harm, not savings. Every primary care physician should know that 5% total body weight loss is enough to start improving blood pressure and blood sugar, and that current medications routinely achieve three to four times that.

But I keep coming back to one patient. She had uterine cancer — the cancer most attributable to obesity, the one where more than half of all cases are caused by excess weight. She was severely obese and wanted desperately to lose weight. She was too scared of bariatric surgery. Her insurance covered zero GLP-1 medications. She couldn’t access treatment. She completed her cancer therapy, and thank God, she remains in remission. But she’s still severely obese, still struggling with the medical consequences, still carrying the psychological burden. She has a cancer that obesity caused, and she can’t get help with the obesity. That’s the gap. Not in the science — in the system.

Who Needs Weight Management Counseling from Day 1?

The highest-yield groups for proactive intervention:

• Women starting adjuvant breast chemotherapy, especially premenopausal or with planned ovarian suppression
• Men starting androgen deprivation therapy for prostate cancer
• Children with ALL on steroid-containing protocols
• Anyone expected to need prolonged corticosteroids
• Breast cancer survivors on aromatase inhibitors, where weight loss may be harder to achieve
• Any cancer patient with BMI above 30 at diagnosis